CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on uniQure (QURE – Research Report). The company’s shares ...

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) yesterday. The company’s shares ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...